1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Sichuan Kelun Pharmaceutical Co., Ltd. Class A

Sichuan Kelun Pharmaceutical Co., Ltd. Class A

SSZSE:002422
42.75
CNY
-0.01
(-0.02%)
1.59EPS
29.75P/E
61.28BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.75
5.61
5.41
6.01
7.94
11.46
12.41
11.51
12.22
13.62
14.76
13.82
11.64
11.88
Basic EPS, GAAP
0.75
0.7
0.45
0.41
0.52
0.85
0.66
0.58
0.78
1.22
1.69
1.86
1.07
1.29
Free Cash Flow per Basic Share
-0.84
-1.08
-0.42
0.25
-0.26
1.14
0.62
0.69
1.31
1.6
2.45
1.78
0.64
- -
Dividend per Share
0.27
0.35
0.43
0.5
0.45
0.69
0.6
0.79
0.7
0.74
0.78
1.15
0.69
1.15
Book Value per Share
6.78
7.46
7.68
7.87
8.2
8.85
9.16
9.38
9.72
11.06
13.12
14.04
15.16
15.47
Tangible Book Value per Share
5.84
6.58
6.72
6.87
7.13
7.71
8.02
8.26
8.68
10.04
12.19
13.21
14.33
14.67
Basic Weighted Avg Shares
1,439
1,431
1,434
1,426
1,440
1,427
1,421
1,430
1,414
1,398
1,453
1,578
1,591
1,580
Sales/Revenue/Turnover
6,831
8,023
7,763
8,566
11,435
16,352
17,636
16,464
17,277
19,038
21,454
21,812
18,513
18,768
Operating Margin (%)
21.52
17.95
14.08
12.68
10.93
12.02
10.27
9.94
9.89
13.3
17.19
20.02
13.44
12.81
Depreciation Expense
326
496
569
651
801
987
1,070
1,155
1,218
1,185
1,244
1,282
1,400
- -
Net Income, GAAP
1,080
1,002
645
585
749
1,213
938
829
1,103
1,705
2,456
2,936
1,702
2,045
Effective Tax Rate (%)
14.89
14.28
20.41
12.86
28.93
4.94
18.69
17.13
26.28
17.59
26.08
21.55
21.91
14.89
Profit Margin (%)
15.8
12.49
8.31
6.83
6.55
7.42
5.32
5.04
6.38
8.96
11.45
13.46
9.19
10.9
Working Capital
4,911
3,050
1,453
-1,451
-273
2,231
-646
2,434
600
4,545
8,297
8,798
10,850
11,373
LT Debt
4,416
3,735
3,416
1,386
3,496
5,449
2,147
5,118
3,522
4,756
2,894
879
736
711
Total Equity
10,024
10,970
11,164
11,466
11,982
12,948
13,906
14,003
14,129
16,871
23,016
26,738
29,294
29,824
Return on Invested Capital (%)
6.79
5.71
2.63
3.09
4.27
6.2
4.45
3.33
3.9
7.07
9.46
11.4
6.21
6.02
Return on Capital (%)
8.77
7.7
5.74
4.57
5.57
8.42
5.72
5.3
6.9
8.19
8.87
8.6
5.04
5
Return on Common Equity (%)
11.63
9.77
5.92
5.22
6.47
9.88
7.23
6.22
8.06
11.53
13.87
13.93
7.29
8.57

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,769
3,075
3,707
LT Borrowings
191
191
184
LT Finance Leases
544
528
527
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,598
1,598
1,591
Market Capitalization
46,903
55,436
61,277

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
20,040
21,285
21,764
Cash, Cash Equivalents & STI
7,489
8,268
9,500
Accounts Receivable, Net
4,673
4,944
4,791
Inventories
3,847
3,793
3,842
Total Current Liabilities
9,190
10,066
10,391
Payables & Accruals
- -
- -
- -
ST Debt
2,769
3,075
3,707
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.58%
16.49%
9.56%
Free Cash Flow
-84.89%
16.61%
-63.78%
Net Income, GAAP
15.56%
21.83%
-42.03%
Sales/Revenue/Turnover
10.24%
2.87%
-15.13%
Total Cash Common Dividend
9.89%
4.35%
-39.79%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,219
5,608
4,962
5,024
21,812
2025
4,390
4,693
- -
5,236
18,513
2026
4,259
4,579
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.67
0.48
0.42
0.29
1.86
2025
0.37
0.26
- -
0.32
1.07
2026
0.29
0.42
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.82
0.02
0.28
1.15
2025
0.02
0.51
- -
0.14
0.69
2026
0.01
0.48
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Si Chuan Liu
Full Time Employees
20,127
Sector
Health technology
Industry
Biotechnology
Address
No.36 Baihua West Road Chengdu SI China 610071
IPO Date
Jun 3, 2010
Website
kelun.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) engages primarily in the research, development, production, and sale of pharmaceutical dosage forms, with a leading position in large-volume injections and a diversified portfolio spanning sterile preparations, oral solids, and biologics in China. The company offers high-volume injections including glucose, sodium chloride, and compound solutions; small-volume injections such as water injections, antibiotic injections like ceftazidime and ceftriaxone sodium; sterile powder needles encompassing dispensed and freeze-dried powders; tablets, capsules, granules, and oral solutions; peritoneal dialysis solutions; antibiotic intermediates and active pharmaceutical ingredients; and pharmaceutical packaging materials, targeting therapeutic areas including oncology, bacterial infections, cardiovascular conditions, anti-tumor treatments, nutritional support, anti-pathogenic microorganisms, respiratory diseases, anti-osteoporosis, and hydroelectrolyte balance. Founded in 1996 and headquartered in Chengdu, Sichuan Province, the company operates production bases across nine Chinese provinces including Sichuan, Hunan, Heilongjiang, and Yunnan, serving domestic markets while exporting select products to over 50 countries; it functions as the core industrial entity within the Kelun Group, alongside listed subsidiaries Kelun-Biotech (06990.HK), focused on innovative biologics such as antibody-drug conjugates, and Chuanning Biotech (301301.SZ), specializing in antibiotic intermediates. Recent developments include Kelun-Biotech's March 2025 exclusive licensing and collaboration agreement with Merck for seven investigational antibody-drug conjugates, featuring a $175 million upfront payment, potential milestones up to $9.3 billion, royalties, and an equity investment, building on prior deals for assets like sacituzumab tirumotecan (SKB264/MK-2870) in global Phase 3 trials for solid tumors; deepened partnership with Ellipses Pharma advancing A400/EP0031 to Phase 2; November-December 2024 IND approvals for SKB501 and SKB500; Kelun-Biotech's 2023 Hong Kong listing; Chuanning Biotech's 2022 Shenzhen GEM listing with entry into synthetic biology; and ongoing global multicenter clinical trials for over ten innovative drugs in oncology, autoimmune, inflammation, and metabolic diseases, supported by more than 1,300 patents.